Neuron-specific enolase (S-NSE) is an enzyme primarily found in nerve cells of the central and peripheral nervous systems. It is an isoform of enolase, an enzyme involved in glycolysis, the process by which cells convert glucose into energy. S-NSE is released into the bloodstream in the presence of nerve cell damage, such as hypoxic or ischemic injury, and is used to assess brain damage and neuroendocrine diseases.
S-NSE is also found in red blood cells and certain neuroectodermal tumors. This means that elevated levels can be observed without the presence of brain injury, for example, in cases of hemolysis or neuroectodermal tumors. However, the analysis is particularly sensitive to hemolysis.
The significance of S-NSE as a biomarker
S-NSE is used in various clinical settings, including:
- Estimating the extent of cellular damage in brain injuries, including hypoxic/ischemic injuries.
- Monitoring treatment response and progression of neuroendocrine tumors.
- Serving as a prognostic marker after cardiac arrest.
One advantage of S-NSE is that it provides a quantitative measure unaffected by sedative medications, making it more reliable than many clinical examination findings or EEG.
S-NSE Testing After Cardiac Arrest
S-NSE is one of the most widely used biomarkers for prognostication after cardiac arrest. Studies have shown that S-NSE levels can help predict poor neurologic outcomes. The largest study to date included 686 patients and reported the following:
Threshold values: A level of ≥48 ng/mL at 48 hours or ≥38 ng/mL at 72 hours after cardiac arrest was associated with a false-positive rate of ≤2% and 58% sensitivity for poor outcomes (based on the Roche assay).
Rising trend: An increase in S-NSE levels between 24 and 48 hours after cardiac arrest strengthened the indication of a poor prognosis.
For optimal clinical utility, a combination of elevated NSE levels at 48 and 72 hours and an upward trend between 24 and 48 hours is recommended as an indicator of poor outcomes. Local threshold values should be adapted to the specific assay used.
Applications of S-NSE
Diagnosis of neurological conditions
- Traumatic brain injury and stroke: S-NSE can help assess the extent of injury and prognosis.
- Hypoxic encephalopathy: Following oxygen deprivation, such as after cardiac arrest, S-NSE is used as an indicator of brain damage.
- Neurodegenerative diseases: Elevated levels may occasionally be observed in Alzheimer’s and Parkinson’s disease.
Monitoring neuroendocrine tumors: S-NSE is used to monitor treatment response and progression of neuroendocrine tumors, particularly small-cell lung cancer. Elevated levels may indicate tumor burden, and reduced levels after treatment often suggest a positive response.
How is S-NSE analyzed?
S-NSE is analyzed through a blood test. The analysis is performed using methods such as:
- ELISA (enzyme-linked immunosorbent assay)
- Immunochemical techniques
To ensure accurate results, it is essential to avoid hemolysis during sample collection.
Interpretation of S-NSE test results
- Normal levels: Indicate the absence of significant nerve damage or neuroendocrine tumors.
- Elevated levels: May indicate brain injuries, neuroendocrine tumors, or other conditions affecting nerve cells.
